**Conclusion/Implications** Our study suggests that third or more CRS in recurrent ovarian cancer is associated with survival benefit. The outcomes of third or more CRS are influenced by the extent of CRS, with complete CRS associated with better outcomes. The decision to offer third or more CRS should be individualized based on patient factors, including overall health status and extent of disease.

## EP258/#917 RECURRENCE-FREE SURVIVAL AND OVERALL SURVIVAL IN EARLY-STAGE OVARIAN CANCER CONSIDERING HOMOLOGOUS RECOMBINATION DEFICIENCY(HRD) STATUS

[1]Won-Ji Kim*, [2]Joseph Noh, [2]Chel Hun Choi, [1]Tae-Joong Kim, [2]Jeong-Won Lee, [3]Byoung Gie Kim, [3]Yoo Young Lee. *[1]Samsung Medical Center, Obstetrics and Gynecology, Gynecologic Cancer Center, Seoul, Korea, Republic of; [2]Samsung Medical Center, Obstetrics and Gynecology, Seoul, Korea, Republic of; [3]Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of*

10.1136/ijgc-2023-IGCS.330

**Introduction** We aimed to determine the recurrence rate and survival outcome among early-stage epithelial ovarian cancer cases in relationship1 to homologous recombination deficiency (HRD) status.

**Methods** We conducted single institution retrospective study of stage I/II EOC patients from 2008 to 2022. HRD was defined as evidence of germline or somatic BRCA mutation. Kaplan-Meier analyses were performed.

**Results** A total of 456 stage I/II patients were included. 22/456 (4.8%) had a germline or somatic BRCA1 mutation 46/456 (10.0%) had a BRCA2 mutation; These 68/456(14.9%) patients comprised the HRD group. The remaining cases were confirmed homologous recombination proficient (HRP, 388/456, 85.1%). The overall recurrence rate was 90/456 (19.7%). The recurrence rate was 68/388 (17.5%) in HRP group and 22/68 (32.4%) in HRD group. Median Recurrence-Free Survival (RFS) was 81 months for HRD group and 109 months for HRP group (p=0.145). Median overall survival was not reached for the HRP group and 147 months (95% CI: 129.6–158.8) for the HRD group (p=0.231), with no significant difference.

**Conclusion/Implications** In this early-stage cohort, despite a high rate of complete surgical staging and adjuvant chemotherapy, recurrence rate was high. The proportion of relapsed patients was higher in the HRD group than in the HRP group, but there was no statistically significant difference. There was no significant difference in RFS and OS between HRD group and HRP group.

## EP259/#509 GENETIC COUNSELING AND TESTING FOR EPITHELIAL OVARIAN CANCER IN A DIVERSE PATIENT POPULATION

[1]Kee-Hwan Kim*, [2]Judy Hayek, [3]Cheyenne Aker, [4]Anjile An, [5]Peilin Zhang, [6]Constantine Gorelick, [6]Margaux Kanis. *[1]NewYork-Presbyterian Brooklyn Methodist Hospital, Obstetrics and Gynecology, Brooklyn, USA; [2]SUNY Downstate Health Sciences University, Gynecologic Oncology, Brooklyn, USA; [3]Weill Cornell Medicine, Obstetrics and Gynecology, New York, USA; [4]Weill Cornell Medicine, Division of Biostatistics, New York, USA; [5]NewYork-Presbyterian Brooklyn Methodist Hospital, Pathology, Brooklyn, USA; [6]NewYork-Presbyterian Brooklyn Methodist Hospital, Gynecologic Oncology, Brooklyn, USA*

10.1136/ijgc-2023-IGCS.331

**Introduction** Genetic testing is recommended for women diagnosed with epithelial ovarian cancer. Results inform surveillance, familial testing, and treatment. We report genetic counseling and testing rates at a tertiary care center with a large minority population.

**Methods** Retrospective cohort study of patients with newly diagnosed epithelial ovarian, fallopian tube, peritoneal cancer between January 2014 and June 2022 at the NewYork-Presbyterian Brooklyn Methodist Hospital.

**Results** 144 patients identified. Mean age at diagnosis was 63 years (SD:13). 51% identified as white, 36% black, 3.5% Asian, 9% other/unknown; 9% were Hispanic and 26% were non-English speaking. 104 (72%) patients received genetic counseling and 99 (69%) received subsequent genetic testing. 95% of those that underwent genetic counseling underwent testing. The genetic counseling and testing rates were not influenced by race, ethnicity, language, insurance type, BMI, family history of cancer. It was associated with significant difference by cancer stage (p<0.01). There was a significant upward trend of proportion of patients that received genetic counseling from 47% in 2015 to 100% in 2022 (p<0.01). Most genetic counseling was performed by a gynecologic oncologist (93%) as opposed to a genetic counselor (6.7%). Overall, 12 (8.3%) patients were BRCA+.

**Conclusion/Implications** Genetic counseling and testing rates within this diverse study population proved to be at least twice as high as the national average of 10–30%, with an increasing year-to-year trend. There were no disparities observed, in contrast to previously published data. BRCA mutation detection was in line with established prevalence within ovarian cancer, indicating adequate screening.



## EP260/#470 EFFECT OF DOSE-DENSE PACLITAXEL PLUS CARBOPLATIN WITH OR WITHOUT BEVACIZUMAB FOR JAPANESE EPITHELIAL OVARIAN CANCER: A SINGLE-CENTER RETROSPECTIVE STUDY

Yuki Kochi*, Satoshi Hosoya, Suguru Odajima, Takafumi Kuroda, Kazuaki Takahashi, Chie Nagata, Motoaki Saito, Nozomu Yanaihara, Hiroshi Tanabe, Kyosuke Yamada, Hirokuni Takano, Aikou Okamoto. *The Jikei University School of Medicine, Obstetrics and Gynecology, Tokyo, Japan*

10.1136/ijgc-2023-IGCS.332

**Introduction** There is still controversy or a lack of evidence regarding the efficacy of dose-dense paclitaxel plus carboplatin (ddTC) and bevacizumab (BEV) for epithelial ovarian cancer (EOC) among Japanese and Westerners. We aimed to compare the survival outcomes between conventional paclitaxel plus carboplatin (TC) with BEV and ddTC with or without BEV among Japanese.

**Methods** We retrospectively analyzed the data from patients newly diagnosed with EOC between 2012 and 2021 at our institutions. The target population was patients with stage III and IV EOC except for poly (adenosine diphosphate-ribose) polymerase inhibitors users. Overall survival (OS) and progression-free survival (PFS) of patients treated with ddTC and ddTC with BEV (ddTC+BEV) were compared to those of patients treated with TC with BEV (TC+BEV). We used